Research Report on China's Antihypertensive Medicine Market, 2012
In recent years, with Chinese people's living standards continuously improving and elderly people
increasing, prevalence rate of hypertension incessantly rises. Presently, there's still no effective means to
cure hypertension. According to the WHO statistics about death of various diseases, death toll of
cardiovascular disease which is represented by hypertension increases from 28.8% of the total mortality
toll in 1997 to 36.0% in 2002. Hypertension is a serious danger to human health.
According to a press release issued by the International Society of Hypertension, the number of global
hypertension or abnormally high blood pressure crowds reaches 972 million, accounting for 26.4% of the
world's adult population. With the invention and application of CCB, ACEI, ARB and other new generation
antihypertensive medicines, the mortality rate of various cardiovascular diseases sharply declines.
Nevertheless, there are still 17 million people across the world die from cardiovascular and
cerebrovascular diseases caused by hypertension and half of them die from acute myocardial infarction
and cerebrovascular embolism. So people pay high attention to antihypertensive medicine market.
Hypertension is defined referring to the largescale epidemiological survey result. China respectively
developed different diagnostic criteria and stages for four times in 1959, 1974, 1979 and 1999 aligning
with different national conditions. In October 1999, by referring to the WHO/ISH hypertension treatment
guidelines, the Chinese Hypertension League defined hypertension as SBP 140mmhg and (or) DBP
90mmhg without taking antihypertensive medicine and according to blood pressure levels, hypertension
is divided into grades 1, 2, 3 which nearly matches light, moderate and severe levels used in the past.
Revising diagnostic criteria for four times reflect that China cardiovascular physicians constantly deepen
the awareness of hypertension prevention and control and advance with the time. Recently, along with
the release of JNC7 and European hypertension prevention and control guidelines and the closure of
some largescale clinical trials, China will develop new hypertension prevention and treatment guidelines
in accordance with national conditions.
Buy your copy of this report @ http://www.reportsnreports.com/reports/166679-research-report-on-
Published: June 2012
Price: Single User License - US$2800 Corporate User License - US$4300
In 2005, China Hypertension Guidelines defined blood pressure of 120~139/80~89 mmHg as normal high
blood pressure while the United States JNC7 defined this level as prehypertension. Both countries
pointed out that such crowds should be given lifestyle intervention, so as not to progress to hypertension.
In 2009, the Chinese Ministry of Health released the result of the fourth National Health Services Survey
which showed that diseases of circulatory system, such as heart disease, cerebrovascular disease,
hypertension, and so on significantly increased, among which doctorconfirmed cases of circulatory
diseases amounted to 114 million, including patients with cerebrovascular diseases increased from 5
million to 13 million, patients with hypertension increased from 14 million to 73 million. Among the
hypertensive patients, the treatment rate was only 24.7% and the control rate only 6.1% while most of the
patients failed to receive effective treatment to reach the normal blood pressure. It is estimated that the
actual population of patients with hypertension currently reaches 200 million with an average annual
increase of over 3 million, and the annual expenses spent in treating hypertension is more than CNY 40
billion. In 2011, the market size of antihypertensive prescription medicine reaches 16.6 billion in China,
with an increase of more than 20% YOY, and the market potential is huge.
In China, the increasing aging trend also means that the typical geriatrics, such as hypertension, stroke,
coronary heart disease, and so on further endangers people's health. For the time being, the situation is
that the medical technology is unable to thoroughly cure these chronic diseases, thus early positive
intervention and preventive treatment are quite significant.
More following information can be acquired through this report:
China's Hypertensive Attack Situation
Current Market of China's Antihypertensive Medicine
Development Trend of China's Antihypertensive Medicine
Following people are recommended to buy this report:
Pharmaceutical Trading Enterprises
Investors and Research Institutes Focusing on Pharmaceutical Industry
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
Connect With Us: